Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

The past three decades saw a dramatic improvement in our understanding of what brings about Alzheimer’s disease. Two proteins are thought to be responsible: amyloid and tau. The most widely accepted theory is that a critical level of amyloid in the brain triggers the build-up of the more toxic tau protein. This has led to several studies testing drugs and vaccines that remove amyloid and tau to see if they can improve or even prevent dementia. Results have been disappointing.

All studies in dementia patients have failed to show improvements, even if amyloid itself was affected. In a prominent case, a vaccine given to patients was shown to have cleared the brain of amyloid of people who nonetheless died of profound dementia.

Over the same period, studies in people destined to develop the condition because of a genetic mutation reported that the changes leading to dementia begin up to 25 years before any symptoms. One logical interpretation is that attempts to find a cure for dementia may have failed because the patients in drug trials were treated too late in the disease process.

Read the full article on The Conversation website, written by Ivan Koychev, Clinical Lecturer in Department of Psychiatry

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Ethics in Mental Health Digital Innovations for Young People in Africa: Digital Campaign

This campaign was led by a team of 29 Early Career Researchers (ECRs) and a Young People's Advisory Group (YPAG) across five African countries. The young people wanted to share contextual and accessible information on digital mental health and ethical issues that are important to them.

The Duchess of Cornwall opens the new Marcela Botnar wing

A new building at the University of Oxford's Botnar Institute for Musculoskeletal Sciences has been opened by The Duchess of Cornwall.

Cancer Research UK to invest £11 million into cancer science in Oxford

A £11 million Cancer Research UK investment has been awarded to the University of Oxford and Oxford-based NHS to catalyse the translation of its world-leading cancer research for patient benefit.

Review highlights risk factors associated with violence in schizophrenia

Researchers at Oxford University’s Department of Psychiatry have found that people with schizophrenia and related disorders are at higher-than-average risk of perpetrating violence, but that the overall risk remains low (less than 1 in 20 in women, and less than 1 in 4 for men over a 35-year period for violent arrests and crimes).

An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections

First comprehensive analysis of global impact of antimicrobial resistance (AMR) estimates resistance itself caused 1.27 million deaths in 2019 - more deaths than HIV/AIDS or malaria - and that antimicrobial-resistant infections played a role in 4.95 million deaths.

Attention and memory deficits persist for months after recovery from mild Covid

Researchers from Oxford’s Department of Experimental Psychology and Nuffield Department of Clinical Neurosciences have shown that people who have had Covid but don’t complain of long Covid symptoms in daily life nevertheless can show degraded attention and memory for up to 6-9 months.